High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 2, 2004, Pages 233-245

  van Laar, Jacob M ^a   McSweeney, Peter A ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Rocky Mountain Cancer Center   (United States)

Author keywords

Hematopoietic stem cell transplantation; Immunosuppression; Systemic sclerosis

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RELAXIN; THYMOCYTE ANTIBODY;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG FATALITY; DRUG MEGADOSE; EUROPE; FRANCE; FUNCTIONAL ASSESSMENT; GENERAL CONDITION IMPROVEMENT; HEART DISEASE; HERPES VIRUS INFECTION; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LOW DRUG DOSE; LUNG DISEASE; LUNG FUNCTION; LUNG INJURY; LUNG INSUFFICIENCY; LUNG TOXICITY; LYMPHOMA; MORTALITY; MULTIPLE ORGAN FAILURE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAFETY; SCORING SYSTEM; SKINFOLD; SYSTEMIC SCLEROSIS; UNITED STATES;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SCLERODERMA, SYSTEMIC; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 4344562726     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.05.005     Document Type: Article

References (54)

1. Clements P.J. Furst D.E. (Eds.), Systemic Sclerosis 1996 Williams & Wilkins Baltimore
2. Weiner E.S. Hildebrandt S. Senecal J.L. et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study Arthritis and Rheumatism 34 1991 68-77
3. Fanning G.C. Welsh K.I. Bunn C. et al. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients British Journal of Rheumatology 37 1998 201-207
4. Roumm A.D. Whiteside T.L. Medsger T.A. Jr Rodnan G.P. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations Arthritis and Rheumatism 27 1984 645-653
5. Harrison N.K. Myers A.R. Corrin B. et al. Structural features of interstitial lung disease in systemic sclerosis American Review of Respiratory Diseases 144 1991 706-713
6. Wells A.U. Lorimer S. Majumdar S. et al. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium European Respiratory Journal 8 1995 266-271
7. Yurovsky V.V. Sutton P.A. Schulze D.H. et al. Expansion of selected V delta 1+ gamma delta T cells in systemic sclerosis patients Journal of Immunology 153 1994 881-891
8. Yurovsky V.V. Wigley F.M. Wise R.A. White B. Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis Human Immunology 48 1996 84-97
9. Shulman H.M. Sullivan K.M. Weiden P.L. et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients American Journal of Medicine 69 1980 204-217
10. Janin-Mercier A. Saurat J.H. Bourges M. et al. The lichen planus like and sclerotic phases of the graft versus host disease in man: an ultrastructural study of six cases Acta Dermato-Venereologica 61 1981 187-193
11. Evans P.C. Lambert N. Maloney S. et al. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma Blood 93 1999 2033-2037
12. Nelson J.L. Furst D.E. Maloney S. et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma Lancet 351 1998 559-562
13. Wilson T.J. Van de Water J. Mohr F.C. et al. Avian scleroderma: evidence for qualitative and quantitative T cell defects Journal of Autoimmunity 5 1992 261-276
14. van de Water J. Haapanen L. Boyd R. et al. Identification of T cells in early dermal lymphocytic infiltrates in avian scleroderma Arthritis and Rheumatism 32 1989 1031-1040
15. Boyd R.L. Wilson T.J. Van De Water J. et al. Selective abnormalities in the thymic microenvironment associated with avian scleroderma, an inherited fibrotic disease of L200 chickens Journal of Autoimmunity 4 1991 369-380
16. Furst D.E. The endothelium in the pathogenesis of systemic sclerosis: is it primary or secondary? Journal des Maladies Vasculaires 24 1999 95-98
17. Blockmans D. Beyens G. Verhaeghe R. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases Clinical Rheumatology 15 1996 148-153
18. Medsger T.A. Jr Masi A.T. Rodnan G.P. et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients Annals of Internal Medicine 75 1971 369-376
19. Giordano M. Valentini G. Migliaresi S. et al. Different antibody patterns and different prognoses in patients with various extent of skin sclerosis Journal of Rheumatology 13 1986 911-916
20. Spooner M.S. LeRoy E.C. The changing face of severe scleroderma in five patients Clinical and Experimental Rheumatology 8 1990 101-105
21. Altman R.D. Medsger T.A. Jr Bloch D.A. et al. Predictors of survival in systemic sclerosis (scleroderma) Arthritis and Rheumatism 34 1991 403-413
22. Bulpitt K.J. Clements P.J. Lachenbruch P.A. et al. Early differentiated connective tissue disease. III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis) Annals of Internal Medicine 118 1993 602-609
23. Silman A.J. Black C.M. Welsh K.I. Epidemiology, demographics, genetics In Clements P.J. & Furst D.E. (Eds.), Systemic Sclerosis 1996 23-50 Williams & Wilkins Baltimore
24. Bryan C. Knight C. Black C.M. Silman A.J. Prediction of five-year survival following presentation with scleroderma. Development of a simple model using three disease factors at first visit Arthritis and Rheumatism 42 1999 2660-2665
25. Clements P. Lachenbruch P. Siebold J. et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis Journal of Rheumatology 22 1995 1281-1285
26. Clements P.J. Hurwitz E.L. Wong W.K. et al. Skin thickness as a predictor and correlate of outcome in systemic sclerosis Arthritis and Rheumatism 43 2000 2445-2454
27. Clements P.J. Furst D.E. Wong W.K. et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial Arthritis and Rheumatism 42 1999 1194-1203
28. Black C.M. Silman A.J. Herrick A.I. et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial Arthritis and Rheumatism 42 1999 299-305
29. Seibold J.R. Korn J.H. Simms R. et al. Recombinant human relaxin in the treatment of scleroderma. A randomised, double blind, placebo controlled trial Annals of Internal Medicine 132 2000 871-879
30. van den Hoogen F.H. Boerbooms M. Swaak A.J. et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial British Journal of Rheumatology 35 1996 364-372
31. Pope J.E. Bellamy N. Seibold J.R. et al. A randomised, controlled trial of methotrexate versus placebo in early diffuse scleroderma Arthritis and Rheumatism 44 2001 1351-1358
32. Åkesson A. Scheja A. Lundin A. Wollheim F.A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide Arthritis and Rheumatism 37 1994 729-735
33. White B. Moore W.C. Wigley F.M. et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Annals of Internal Medicine 132 2000 947-954
34. Clements P. Lachenbruch P. Siebold J. et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis Journal of Rheumatology 22 1995 1281-1285
35. Steen V.D. Medsger T.A. Jr The value of the Health Assessment Questionnaire and special patient generated scales to demonstrate change in systemic sclerosis over time Arthritis and Rheumatism 40 1997 1984-1991
36. Tyndall A. Black C. Finke J. et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation Lancet 349 1997 254
37. Martini A. Maccario R. Ravelli A. et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis Arthritis and Rheumatism 42 1999 807-811
38. Clements P.J. Furst D.E. Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation Journal of Rheumatology supplement 48 1997 85-88
39. McSweeney P.A. Nash R.A. Storb R. et al. Autologous stem cell transplantation for autoimmune diseases: issues in protocol development Journal of Rheumatology supplement 48 1997 79-84
40. Tyndall A. Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) British Journal of Rheumatology 36 1997 390-392
41. Binks M. Passweg J.R. Furst D. et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease Annals of Rheumatic Diseases 60 2000 577-584
42. Rosen O. Massenkeil G. Hiepe F. et al. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis: no evidence for cyclophosphamide-induced cardiomyopathy Bone Marrow Transplantation 27 2001 657-658
43. McSweeney P.A. Nash R.A. Sullivan K.M. et al. High-dose immunosuppressive therapy for severe systemic sclerosis - initial outcomes Blood 100 2002 1602-1610
44. O'Dell J.R. Steigerwald J.C. Kennaugh R.C. et al. Lack of clinical benefit after treatment of systemic sclerosis with total lymphoid irradiation Journal of Rheumatology 16 1989 1050-1054
45. Varga J. Haustein U.F. Creech R.H. et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis Journal of the American Medical Association 265 1991 3292-3295
46. Abu-Shakra M. Lee P. Exaggerated fibrosis in patients with systemic sclerosis (scleroderma) following radiation therapy Journal of Rheumatology 20 1993 1601-1603
47. Aref I. Cross P. Nair B. Case report: severe fibrosis in a patient with scleroderma and previous radiotherapy - a case report and literature review British Journal of Radiology 69 1996 1055-1056
48. Nash R.A. Dansey R. Storek J. et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases Biology of Blood and Marrow Transplantation 9 2003 583-591
49. Farge D. Marolleau J.P. Zohar S. et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study British Journal of Haematology 119 2002 1-14
50. Farge D. Passweg J. van Laar J.M. et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: an extended report from the EBMT/EULAR Registry Annals of the Rheumatic Diseases 2004 in press
51. Schnabel A. Reuter M. Gross W.L. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases Arthritis and Rheumatism 41 1998 1215-1220
52. Várai G. Earle L. Jimenez S.A. et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease Journal of Rheumatology 25 1998 1325-1329
53. Davas E.M. Peppas C. Maragou M. et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma Clinical Rheumatology 18 1999 455-461
54. Subcommittee for Scleroderma Driteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis and Rheumatism 23 1980 581-590